title: Drug discovery using spirooxindole cores: Success and Challenges [corrected].
abstract: The identification of novel anticancer agents with high efficacy and low toxicity has always been an intriguing topic in medicinal chemistry. The unique structural features of spirooxindoles together with diverse biological activities have made them promising structures in new drug discovery. “Among spirooxindoles, CFI-400945, recently discovered by Sampson et al., is a potent PLK4 inhibitor, which has entered phase I clinical trials for the treatment of solid tumors. However, questions remain as to whether PLK4 is the only relevant therapeutic target for CFI-400945. To highlight this significant progress of CFI-400945 in last two years, this review centers on the identification from a focused kinase library, structural optimizations and strategies involved, structure-activity relationships, modes of action, target validation, chemical synthesis and, more importantly, the kinase selectivity between PLK4 and other targets [corrected].
authors: School of Pharmaceutical Sciences and New Drug Research & Development Center, Zhengzhou University, Zhengzhou 450001, PR China. Electronic address: zzuyubin@hotmail.com.
authors: Bin
authors: B
authors: Yu
authors: School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, PR China.
authors: Zhiqiang
authors: Z
authors: Yu
authors: School of Pharmaceutical Sciences and New Drug Research & Development Center, Zhengzhou University, Zhengzhou 450001, PR China.
authors: Ping-Ping
authors: PP
authors: Qi
authors: School of Pharmaceutical Sciences and New Drug Research & Development Center, Zhengzhou University, Zhengzhou 450001, PR China. Electronic address: dqyu@imm.ac.cn.
authors: De-Quan
authors: DQ
authors: Yu
authors: School of Pharmaceutical Sciences and New Drug Research & Development Center, Zhengzhou University, Zhengzhou 450001, PR China. Electronic address: liuhm@zzu.edu.cn.
authors: Hong-Min
authors: HM
authors: Liu
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D055808:Drug Discovery; D006801:Humans; D007191:Indazoles / Q000008:administration & dosage* / Q000494:pharmacology; D007211:Indoles / Q000008:administration & dosage* / Q000494:pharmacology; D009369:Neoplasms / Q000188:drug therapy*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
chemical_list: C000592365:2-(3-(4-((2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro(cyclopropane-1,3'-indolin)-2'-one; D000970:Antineoplastic Agents; D007191:Indazoles; D007211:Indoles; D017346:Protein Serine-Threonine Kinases
keywords: Anticancer drug; CFI-400945; Kinase selectivity; Spirooxindoles